PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma

Abstract

Renal cell carcinoma (RCC) is one of the most common malignancies. Despite the rapid development of the oncology research and surgical treatment, the prognosis of RCC has not significantly improved. Thus, exploration of the pathological molecular mechanism and development of new therapeutic targets of RCC are of great importance. Herein, by bioinformatic analysis and in vitro cell experiments, we report that, the expression of pseudouridine synthase 1 (PUS1), belonging to the family of PUS enzymes that participate in RNA modifications, is closely associated with RCC progression. In addition, the upregulated PUS1 expression results in the elevated RCC cancer cell viability, migration, invasion and colony formation ability, whereas the decreased PUS1 expression exerts the opposite effects on RCC cells. Thus, our findings show the potential role of PUS1 in RCC cells, providing with evidence that PUS1 is involved in RCC progression, which may help contribute to RCC diagnosis and intervention in clinic.

The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues

“…Altered pseudouridine deposition has also been associated with metastasis, particularly through PUS1 and PUS7 dysregulation ( 129 , 130 ). PUS7 is found to be overexpressed in CRC ( 129 ).…”

“…PUS1 pseudouridylates tRNAs at positions 1, 26, 27, 28, 34, 36, 65 and 67 ( 131 ). High PUS1 expression is closely associated with renal cell carcinoma (RCC) ( 130 ). In fact, up-regulation of PUS1 enhances RCC cancer cell viability, migration, invasion and colony formation ability, while decreased PUS1 expression exerts the opposite effects on RCC cells ( 130 ).…”

“…High PUS1 expression is closely associated with renal cell carcinoma (RCC) ( 130 ). In fact, up-regulation of PUS1 enhances RCC cancer cell viability, migration, invasion and colony formation ability, while decreased PUS1 expression exerts the opposite effects on RCC cells ( 130 ). However, the mechanism involving tRNA pseudouridylation and both cancer types is not yet fully understood ( 129 , 130 ).…”